Parameter | All patients | Patients without bone metastases (m0BCR) | Patients with bone metastases (m1BCR) |
---|---|---|---|
n | 55 | 48 | 7 |
Median age in years [range] | |||
At prostate cancer diagnosis | 65 [46–78] | 65 [46–78] | 66 [55–76] |
At first biochemical recurrence | 71 [50–87] | 71 [50–86] | 72 [56–87] |
Initial group according to d’Amico classification | |||
Low risk | 7 (13%) | 7 | 0 |
Intermediate risk | 23 (42%) | 20 | 3 |
High risk | 19 (35%) | 15 | 4 |
Unknown | 6 (10%) | 6 | 0 |
Initial Gleason score | |||
≤ 6 | 13 (24%) | 13 | 0 |
7 | 30 (55%) | 25 | 5 |
≥ 8 | 8 (15%) | 8 | 0 |
Unknown | 4 (6%) | 2 | 2 |
Initial International Society of Urological Pathologists (ISUP) 2014 grade group | |||
1 | 13 (24%) | 13 | 0 |
2 | 17 (30%) | 13 | 4 |
3 | 10 (18%) | 10 | 0 |
4 | 7 (13%) | 7 | 0 |
5 | 1 (2%) | 1 | 0 |
Unknown | 7 (13%) | 4 | 3 |
First line treatment | |||
Surgery (prostatectomy ± lymph node dissection) | 29 (53%) | 28 | 1 |
Definitive radiation therapy ± ADT | 19 (35%) | 14 | 5 |
Other local treatment options* | 7 (12%) | 6 | 1 |
Median time to biochemical recurrence in months [range] | 89 [4–228] | 92 [4–228] | 87 [6–149] |
Median PSA serum value at BCR imaging workup ng/ml [range] | 4.7 [0.2–137] | 4.1 [0.2–52] | 16.5 [1.0–137] |
Management of biochemical recurrence after imaging workup | |||
Salvage radiation therapy (prostatic lodge ± pelvic lymph nodes) ± ADT | 8 (15%) | 8 | 0 |
ADT | 27 (49%) | 22 | 5 |
Surveillance | 9 (16%) | 9 | 0 |
Other treatment option** | 11 (20%) | 9 | 2 |